Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched and acquired products show growth.

Here’s what the company reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

• Earnings per share: 75 cents adjusted vs. 72 cents expected
• Revenue: $14.45 billion vs. $13.79 billion expected

The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Pfizer is focused on several crucial data releases this year, including late-stage trial results on an experimental targeted drug in lung cancer.